Full Title
A Measurable Residual Disease (MRD) Focused, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial (MM1YA-CTG01) (CIRB)Purpose
For people with newly diagnosed acute myeloid leukemia (AML), the more leukemia cells are destroyed, the better their long-term outcomes. In this study, researchers want to see adding venetoclax to standard chemotherapy (daunorubicin/cytarabine) or giving it with azacitidine works better than standard therapy for getting rid of the small amount of remaining leukemia cells. The people in this study include young adults with intermediate-risk AML.
Venetoclax is in a class of medications called BCL-2 inhibitors. It may stop the growth of cancer cells by blocking BCL-2, a protein cancer cells need to survive.
If you join this study, you will get one of these regimens of treatment:
- Daunorubicin, cytarabine, and venetoclax
- Azacitidine and venetoclax
- Daunorubicin and cytarabine
Contact
For more information or to see if you can join this study, please call 888-874-5087. We can help answer any questions and connect you (or your patient) with the study team.